Mylan Pulls Generic Gilenya Application Over Study Concerns
As Accord Withdrawal Of Erlotinib Also Revealed By EMA's CHMP
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.
